Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2025
Hormone therapy with different administration routes for patients with perimenopausal syndrome: a systematic review and network meta-analysis.
СтатьяNetwork Meta-AnalysisСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Liping, Luo Xinrui, Ren Mulan, Wang Yan
Аннотация
PURPOSE: To comprehensively compare and rank hormone therapy for patients with perimenopausal syndrome.
METHODS: A comprehensive search was conducted on PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, and Wanfang databases from inception to August 20, 2024. The quality of the included randomized controlled trials (RCTs) were measured by the Cochrane risk of bias tool. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was applied to grade the quality of evidence in this network meta-analysis. Network plots were depicted to show direct and indirect comparisons of hormone therapy for each outcome. The influences of different hormone therapy on the outcomes were illustrated via forest plots and league tables. Rank probabilities showed the ranking of different administration routes.
RESULTS: Seven studies involving 704 perimenopausal syndrome patients were included. The rank probabilities suggested that oral estradiol (E2) combined with medroxyprogesterone and general health guidance had the highest likelihood to be the optimal therapy for the severity of menopausal syndrome. General health guidance combined with oral E2 was less likely to have a nausea and vomiting, and breast pain.
CONCLUSION: Oral E2 and medroxyprogesterone or general health guidance combined with oral E2 may be the effective and safe option for the management of perimenopausal syndrome.
METHODS: A comprehensive search was conducted on PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, and Wanfang databases from inception to August 20, 2024. The quality of the included randomized controlled trials (RCTs) were measured by the Cochrane risk of bias tool. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was applied to grade the quality of evidence in this network meta-analysis. Network plots were depicted to show direct and indirect comparisons of hormone therapy for each outcome. The influences of different hormone therapy on the outcomes were illustrated via forest plots and league tables. Rank probabilities showed the ranking of different administration routes.
RESULTS: Seven studies involving 704 perimenopausal syndrome patients were included. The rank probabilities suggested that oral estradiol (E2) combined with medroxyprogesterone and general health guidance had the highest likelihood to be the optimal therapy for the severity of menopausal syndrome. General health guidance combined with oral E2 was less likely to have a nausea and vomiting, and breast pain.
CONCLUSION: Oral E2 and medroxyprogesterone or general health guidance combined with oral E2 may be the effective and safe option for the management of perimenopausal syndrome.